Header Logo

Connection

Leslie Harrold to Arthritis, Rheumatoid

Back to Details
This is a "connection" page, showing publications Leslie Harrold has written about Arthritis, Rheumatoid.
Leslie Harrold
Connection Strength
16.182
Arthritis, Rheumatoid
  1. Harrold LR, Bingham CO, Pope JE, O'Brien J, Moore PC, Roberts-Toler C, Yu M, Sweet LL, Shelbaya A, Masri KR. Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry. Clin Rheumatol. 2025 Feb; 44(2):635-648.
    View in: PubMed
    Score: 0.729
  2. O'Brien J, Park SH, Blachley T, Marchese M, Middaugh N, Wittstock K, Harrold LR. Disparities in burden of disease in patients with rheumatoid arthritis across racial and ethnic groups. Clin Rheumatol. 2024 Mar; 43(3):921-927.
    View in: PubMed
    Score: 0.685
  3. Harrold LR, Wittstock K, Kelly S, Han X, Zhuo J, Schrader A, Middaugh N, Moore PC, Khaychuk V. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive. Adv Rheumatol. 2024 01 19; 64(1):10.
    View in: PubMed
    Score: 0.684
  4. Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Prevalence of Sj?gren's syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. Clin Rheumatol. 2020 Jun; 39(6):1899-1905.
    View in: PubMed
    Score: 0.523
  5. Harrold LR, Shan Y, Connolly SE, Alemao E, Rebello S, Guo L, Kremer JM. Association among anti-citrullinated protein antibody status, erosive disease and healthcare resource utilization in patients with rheumatoid arthritis. Curr Med Res Opin. 2020 02; 36(2):337-342.
    View in: PubMed
    Score: 0.510
  6. Harrold LR, Patel PA, Griffith J, Litman HJ, Feng H, Schlacher CA, Kremer JM. Assessing disease severity in bio-na?ve patients with RA on treatment with csDMARDs: insights from the Corrona Registry. Clin Rheumatol. 2020 Feb; 39(2):391-400.
    View in: PubMed
    Score: 0.510
  7. Harrold LR, Griffith J, Zueger P, Litman HJ, Gershenson B, Islam SS, Barr CJ, Guo D, Fay J, Greenberg JD. Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry. J Rheumatol. 2020 07 01; 47(7):959-967.
    View in: PubMed
    Score: 0.502
  8. Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR. Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. J Rheumatol. 2018 10; 45(10):1353-1360.
    View in: PubMed
    Score: 0.465
  9. Harrold LR, Reed GW, John A, Barr CJ, Soe K, Magner R, Saunders KC, Ruderman EM, Haselkorn T, Greenberg JD, Gibofsky A, Harrington JT, Kremer JM. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2018 03; 70(3):379-387.
    View in: PubMed
    Score: 0.453
  10. Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M. One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry. Arthritis Res Ther. 2018 01 02; 20(1):2.
    View in: PubMed
    Score: 0.450
  11. Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-a Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. J Rheumatol. 2018 01; 45(1):32-39.
    View in: PubMed
    Score: 0.445
  12. Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Clin Rheumatol. 2017 Sep; 36(9):2135-2140.
    View in: PubMed
    Score: 0.436
  13. Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol. 2017 Jun; 36(6):1215-1220.
    View in: PubMed
    Score: 0.424
  14. Harrold LR, Reed GW, Karki C, Magner R, Shewade A, John A, Kremer JM, Greenberg JD. Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care Res (Hoboken). 2016 12; 68(12):1888-1893.
    View in: PubMed
    Score: 0.417
  15. Harrold LR, Reed GW, Solomon DH, Curtis JR, Liu M, Greenberg JD, Kremer JM. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther. 2016 12 01; 18(1):280.
    View in: PubMed
    Score: 0.417
  16. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Kavanaugh A, Saunders KC, Shan Y, Spruill TM, Pappas DA, Greenberg JD. Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations. Arthritis Res Ther. 2016 Apr 26; 18:94.
    View in: PubMed
    Score: 0.400
  17. Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry. Arthritis Res Ther. 2015 Sep 18; 17:256.
    View in: PubMed
    Score: 0.384
  18. Harrold LR, Reed GW, Shewade A, Magner R, Saunders KC, John A, Kremer JM, Greenberg JD. Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry. J Rheumatol. 2015 Jul; 42(7):1090-8.
    View in: PubMed
    Score: 0.374
  19. Harrold LR, Reed GW, Harrington JT, Barr CJ, Saunders KC, Gibofsky A, Greenberg JD, John A, Devenport J, Kremer JM. The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network. BMC Musculoskelet Disord. 2014 Nov 21; 15:389.
    View in: PubMed
    Score: 0.362
  20. Harrold LR, Reed GW, Kremer JM, Curtis JR, Solomon DH, Hochberg MC, Greenberg JD. The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. Ann Rheum Dis. 2015 Feb; 74(2):430-6.
    View in: PubMed
    Score: 0.339
  21. Greenberg JD, Spruill TM, Shan Y, Reed G, Kremer JM, Potter J, Yazici Y, Ogedegbe G, Harrold LR. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med. 2013 Dec; 126(12):1089-98.
    View in: PubMed
    Score: 0.339
  22. Harrold LR, Gurwitz JH, Briesacher BA. Dr. Harrold, et al reply. J Rheumatol. 2013 Aug; 40(8):1462.
    View in: PubMed
    Score: 0.331
  23. Harrold LR, Briesacher BA, Peterson D, Beard A, Madden J, Zhang F, Gurwitz JH, Soumerai SB. Cost-related medication nonadherence in older patients with rheumatoid arthritis. J Rheumatol. 2013 Feb; 40(2):137-43.
    View in: PubMed
    Score: 0.319
  24. Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology (Oxford). 2013 Oct; 52(10):1785-94.
    View in: PubMed
    Score: 0.317
  25. Harrold LR, Peterson D, Beard AJ, Gurwitz JH, Briesacher BA. Time trends in medication use and expenditures in older patients with rheumatoid arthritis. Am J Med. 2012 Sep; 125(9):937.e9-15.
    View in: PubMed
    Score: 0.306
  26. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G, Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. Arthritis Rheum. 2012 Mar; 64(3):630-8.
    View in: PubMed
    Score: 0.300
  27. Harrold LR, Li W, Yood RA, Fuller J, Gurwitz JH. Identification of patients with arthritis and arthritis-related functional limitation using administrative data. J Public Health Manag Pract. 2008 Sep-Oct; 14(5):487-97.
    View in: PubMed
    Score: 0.235
  28. Fukui S, Winkelmayer WC, Tedeschi SK, Marrugo J, Guan H, Harrold L, Litman HJ, Shinozaki T, Solomon DH. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann Rheum Dis. 2025 Feb; 84(2):201-209.
    View in: PubMed
    Score: 0.183
  29. Baker JF, Reed G, Mikuls TR, Thiele GM, Pappas DA, Charles-Schoeman C, Guma M, Harrold LR, Curtis JR, Kremer JM. Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Rheumatol. 2025 Mar; 77(3):263-271.
    View in: PubMed
    Score: 0.182
  30. Hsiao B, Downs JS, Lanyon M, Blalock SJ, Curtis JR, Harrold LR, Nowell WB, Wiedmeyer C, Venkatachalam S, Patterson MT, Gavigan K, Stradford L, Ali D, Fraenkel L. Understanding Heterogeneity in Patients' Conceptualisation of Treatment for Rheumatoid Arthritis: A Cluster Analysis. BMJ Open. 2023 09 04; 13(9):e070848.
    View in: PubMed
    Score: 0.167
  31. Sparks JA, Harrold LR, Simon TA, Wittstock K, Kelly S, Lozenski K, Khaychuk V, Michaud K. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review. Semin Arthritis Rheum. 2023 10; 62:152249.
    View in: PubMed
    Score: 0.166
  32. Galvao RW, Curtis JR, Harrold LR, Wu Q, Xie F, George MD. Accuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2023 11; 32(11):1271-1279.
    View in: PubMed
    Score: 0.165
  33. Yun H, Chen L, Roy JA, Greenberg J, Harrold LR, George MD, Curtis JR. Rheumatoid Arthritis Disease Activity and Hospitalized Infection in a Large US Registry. Arthritis Care Res (Hoboken). 2023 08; 75(8):1639-1647.
    View in: PubMed
    Score: 0.161
  34. Yoshida K, Harrold LR, Middaugh N, Guan H, Stryker S, Karis E, Solomon DH. Examining the potential direct cardiovascular benefit of tumor-necrosis factor inhibitor in rheumatoid arthritis: Natural and controlled direct effect analyses. Pharmacoepidemiol Drug Saf. 2023 04; 32(4):407-415.
    View in: PubMed
    Score: 0.157
  35. Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 11; 74(11):1909-1916.
    View in: PubMed
    Score: 0.154
  36. Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 08; 73(8):1114-1124.
    View in: PubMed
    Score: 0.144
  37. Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold LR, Feathers VL, Shadick N, Weinblatt ME, Reed G. The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. J Rheumatol. 2021 12; 48(12):1776-1783.
    View in: PubMed
    Score: 0.138
  38. Owensby JK, Chen L, O'Beirne R, Ruderman EM, Harrold LR, Melnick JA, Safford MM, Curtis JR, Danila MI. Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2020 07; 72(7):933-941.
    View in: PubMed
    Score: 0.134
  39. Harrold LR, Shan Y, Rebello S, Kramer N, Connolly SE, Alemao E, Kelly S, Kremer JM, Rosenstein ED. Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sj?gren's syndrome enrolled in a large observational US registry. Rheumatol Int. 2020 Aug; 40(8):1239-1248.
    View in: PubMed
    Score: 0.133
  40. Solomon DH, Yu Z, Katz JN, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Smolen JS, Losina E, Lu B. Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2019 09; 71(9):1243-1248.
    View in: PubMed
    Score: 0.125
  41. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019; 14(1):e0210459.
    View in: PubMed
    Score: 0.121
  42. Zak A, Corrigan C, Yu Z, Bitton A, Fraenkel L, Harrold L, Smolen JS, Solomon DH. Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial. Rheumatology (Oxford). 2018 11 01; 57(11):1933-1937.
    View in: PubMed
    Score: 0.119
  43. Solomon DH, Lu B, Yu Z, Corrigan C, Harrold LR, Smolen JS, Fraenkel L, Katz JN, Losina E. Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial. Arthritis Care Res (Hoboken). 2018 10; 70(10):1551-1556.
    View in: PubMed
    Score: 0.118
  44. Yu Z, Lu B, Agosti J, Bitton A, Corrigan C, Fraenkel L, Harrold LR, Losina E, Katz JN, Solomon DH. Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2018 05; 70(5):801-806.
    View in: PubMed
    Score: 0.115
  45. Curtis JR, Greenberg JD, Harrold LR, Kremer JM, Palmer JL. Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. Semin Arthritis Rheum. 2018 02; 47(4):472-477.
    View in: PubMed
    Score: 0.109
  46. Solomon DH, Losina E, Lu B, Zak A, Corrigan C, Lee SB, Agosti J, Bitton A, Harrold LR, Pincus T, Radner H, Yu Z, Smolen JS, Fraenkel L, Katz JN. Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial. Arthritis Rheumatol. 2017 07; 69(7):1374-1380.
    View in: PubMed
    Score: 0.108
  47. Curtis JR, Chen L, Greenberg JD, Harrold L, Kilgore ML, Kremer JM, Solomon DH, Yun H. The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf. 2017 Mar; 26(3):310-319.
    View in: PubMed
    Score: 0.105
  48. Boytsov N, Harrold LR, Mason MA, Gaich CL, Zhang X, Larmore CJ, Rebello S, Araujo AB. Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. Curr Med Res Opin. 2016 12; 32(12):1959-1967.
    View in: PubMed
    Score: 0.102
  49. Rathbun AM, Harrold LR, Reed GW. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers. Clin Ther. 2016 Jul; 38(7):1759-1772.e3.
    View in: PubMed
    Score: 0.101
  50. Curtis JR, Bharat A, Chen L, Greenberg JD, Harrold L, Kremer JM, Sommers T, Pappas D. Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. J Rheumatol. 2016 06; 43(6):1027-9.
    View in: PubMed
    Score: 0.100
  51. Solomon DH, Lee SB, Zak A, Corrigan C, Agosti J, Bitton A, Harrold L, Losina E, Lu B, Pincus T, Radner H, Smolen J, Katz JN, Fraenkel L. Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial. Semin Arthritis Rheum. 2016 08; 46(1):81-7.
    View in: PubMed
    Score: 0.099
  52. Herrinton LJ, Harrold L, Salman C, Liu L, Goldfien R, Asgari M, Gelfand JM, Wu JJ, Curtis JR. Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998-2009. Perm J. 2016; 20(1):4-12.
    View in: PubMed
    Score: 0.098
  53. Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015 May; 67(6):765-75.
    View in: PubMed
    Score: 0.093
  54. Curtis JR, Chen L, Bharat A, Delzell E, Greenberg JD, Harrold L, Kremer J, Setoguchi S, Solomon DH, Xie F, Yun H. Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. Arthritis Care Res (Hoboken). 2014 Dec; 66(12):1790-8.
    View in: PubMed
    Score: 0.091
  55. Rathbun AM, Harrold LR, Reed GW. Temporal associations between the different domains of rheumatoid arthritis disease activity and the onset of patient-reported depressive symptoms. Clin Rheumatol. 2015 Apr; 34(4):653-63.
    View in: PubMed
    Score: 0.089
  56. Rathbun AM, Harrold LR, Reed GW. A description of patient- and rheumatologist-reported depression symptoms in an American rheumatoid arthritis registry population. Clin Exp Rheumatol. 2014 Jul-Aug; 32(4):523-32.
    View in: PubMed
    Score: 0.088
  57. Curtis JR, Shan Y, Harrold L, Zhang J, Greenberg JD, Reed GW. Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. Arthritis Care Res (Hoboken). 2013 Oct; 65(10):1707-12.
    View in: PubMed
    Score: 0.084
  58. Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, Hochberg MC, Reed G, Tsao P, Greenberg JD. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014 Feb; 43(4):489-97.
    View in: PubMed
    Score: 0.083
  59. Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA. Cardiovascular risk in rheumatoid arthritis: comparing TNF-a blockade with nonbiologic DMARDs. Am J Med. 2013 Aug; 126(8):730.e9-730.e17.
    View in: PubMed
    Score: 0.083
  60. Spruill TM, Ogedegbe G, Harrold LR, Potter J, Scher JU, Rosenthal PB, Greenberg JD. Association of medication beliefs and self-efficacy with adherence in urban Hispanic and African-American rheumatoid arthritis patients. Ann Rheum Dis. 2014 Jan; 73(1):317-8.
    View in: PubMed
    Score: 0.083
  61. Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, Solomon DH, Curtis JR, Lewis JD, Saag KG. Association between anti-TNF-a therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013 Apr; 22(4):394-402.
    View in: PubMed
    Score: 0.080
  62. Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2013 Nov; 72(11):1813-8.
    View in: PubMed
    Score: 0.079
  63. Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord. 2012 May 31; 13:85.
    View in: PubMed
    Score: 0.076
  64. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, Dehoratius R, Kishimoto M, Kremer JM. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012 Jul; 71(7):1134-42.
    View in: PubMed
    Score: 0.075
  65. Furst DE, Pangan AL, Harrold LR, Chang H, Reed G, Kremer JM, Greenberg JD. Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care Res (Hoboken). 2011 Jun; 63(6):856-64.
    View in: PubMed
    Score: 0.071
  66. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Arthritis Care Res (Hoboken). 2010 Jan 15; 62(1):101-7.
    View in: PubMed
    Score: 0.065
  67. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford). 2009 Jun; 48(6):686-90.
    View in: PubMed
    Score: 0.062
  68. Navarro-Mill?n I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS One. 2016; 11(3):e0149781.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.